A clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases, or RTKs, for the treatment of cancer and other diseases with significant unmet need.
Lead Underwriter
Leerink Partners LLC, Stifel Nicolaus & Company, Incorporated.
Co-Managers
Guggenheim Securities, LLC, Janney Montgomery Scott LLC
